Gene therapy biotech Locanabio to shutter by year’s end
02 Nov 2023
Gene Therapy
Gene therapy biotech Locanabio will shut down by the end of this year, the startup’s CEO posted on LinkedIn Wednesday afternoon.
“While we continue to believe in the potential of our RNA-targeted gene therapy platform to deliver transformative therapies, the decision was made due to the time and capital required to deliver clinical data in the current challenging funding environment,” CEO Jim Burns wrote in the post. Burns joined the company in 2019 after leading Casebia Therapeutics and, before that, heading up R&D at Sanofi.
Preview
Source: EndPoints
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
SIGN UP
LOG IN
BECOME A PREMIUM SUBSCRIBER
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
-Targets
-Drugs
-Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.